This project team will create a White Paper with recommendations for listings to include in Clinical Study Reports based on shared learning from cross-industry participants, to address changes in data availability over time.
White Paper providing recommendations for listings to include CSRs and submissions (if any), with a summary of example alternatives to static listings.
Public Review
Final Paper
Q12021
Q22021
Project Members
Organisation
Anna Leath
Eli Lilly
Kim Musgrave
Amgen
Maria Dalton
GSK
Mary Nilsson
Eli Lilly
Raj Phadtare
Corvus Pharma
Q22021
White paper went out for public review. Review period has been extended to allow for expected feedback from the FDA. Hoping to have this finalised for Q3.